FDA Approves New Alzheimer's Drug: Lecanemab

The FDA has approved lecanemab, a new drug for early-stage Alzheimers, targeting amyloid plaques. While promising, it doesnt cure Alzheimers and has potential side effects. This approval marks a significant step in managing early Alzheimers, with ongoing research to fully understand its long-term impact. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/81fdde3845ad5a8b